title: Factor VIII and DDAVP reverse the effect of recombinant desulphatohirudin (CGP 39393) on bleeding in the rat.
abstract: The infusion of a high dose of recombinant desulphatohirudin HVI (CGP 39393) for 40 min at 30 micrograms/kg/min, resulted in a prolongation of bleeding time in the rat when evaluated using transection of the tail. The prolonged bleeding was evident both immediately, and 30 min after cessation of the infusion of hirudin (CGP 39393). Bleeding time returned to normal after 60 min. The effect of several agents, reported to be successful in reducing bleeding tendencies in man, were evaluated in this rat model. The agents were administered immediately following cessation of the CGP 39393 infusion and their ability to normalize the prolonged bleeding-time, observed at 30 min after cessation of the CGP 39393 infusion, determined. Desmopressin (DDAVP), recombinant factor VIII and Vueffe reduced the bleeding time to the control range but did not exert any significant effects on the bleeding time in rats which did not receive CGP 39393. Epsilon-aminocaproic acid (EACA) and recombinant factor VII were ineffective, at the doses used. In conclusion, DDAVP, factor VIII and Vueffe are effective in reversing the effect of direct thrombin inhibition on bleeding in the rat.
authors.affiliation: Thrombosis Research Unit, Ciba-Geigy Pharmaceuticals, Horsham, West Sussex, UK.
authors.forename: K D
authors.initials: KD
authors.lastname: Butler
authors.forename: S L
authors.initials: SL
authors.lastname: Dolan
authors.forename: M D
authors.initials: MD
authors.lastname: Talbot
authors.forename: R B
authors.initials: RB
authors.lastname: Wallis
mesh_terms: D015119:Aminocaproic Acid / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D001760:Bleeding Time; D001777:Blood Coagulation / Q000187:drug effects*; D003894:Deamino Arginine Vasopressin / Q000494:pharmacology* / Q000627:therapeutic use; D005169:Factor VIII / Q000494:pharmacology* / Q000627:therapeutic use; D015942:Factor VIIa / Q000494:pharmacology / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control*; D006629:Hirudins / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors / Q000633:toxicity; D008297:Male; D010455:Peptides / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors / Q000494:pharmacology / Q000627:therapeutic use / Q000633:toxicity
chemical_list: D005343:Fibrinolytic Agents; D006629:Hirudins; D010455:Peptides; D011994:Recombinant Proteins; C082195:Vueffe; D005169:Factor VIII; D015942:Factor VIIa; D003894:Deamino Arginine Vasopressin; C060225:desirudin; D015119:Aminocaproic Acid